Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

Sponsor
Peking University People's Hospital
Study ID
NCT07617285
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • AML
  • Refractory/Relapse Acute Myeloid Leukemia

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • CAR-T cells chimeric antigen receptor T cells — DRUG
    Conditioning regimen: Days -9 to -3: Venetoclax administered with a target dose of 200 mg/day. Days -5 to -4: Cytarabine administered at 500 mg/m²/day. Days -5 to -3: Cyclophosphamide at 300 mg/m²/day plus Fludarabine at 30 mg/m²/day. Day 0: Infusion of CT0890B CAR-T cells at one of four dose levels using an i3+3 Dose-Escalation Design: 1.5 × 10⁸ total cells, 3.0 × 10⁸ total cells, 4.5 × 10⁸ total cells, 6.0 × 10⁸ total cells

Study Details

A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Key Dates

First listed
Jun 1, 2026
Start date
May 7, 2026
Status verified
May 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2029

Study Design

Enrollment
27 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CAR-T cells chimeric antigen receptor T cells
    CT0890B cells infusion

Primary Outcome Measure

Adverse Events (AE) after CT0890B infusion [ Time Frame: 12 months after CT890B infusion ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies